Buy CMPX by Oct 20, 2026.

CMPX is a biotech that collapsed due to trial crossover, even though response rate and progression-free survival were strongly positive. The major rerating catalyst is FDA feedback confirming that the existing ORR/PFS data can support a BLA without another trial. The meeting is expected around early to mid August. Favorable feedback could restore much of the value the market removed, but unfavorable would seriously damage the thesis. This is biotech and can easily go either way. Invest at your own …